Free Trial

HEALTHCARE: Johnson & Johnson (JNJ: Aaa/AAA neg): Results Preview 17th July

HEALTHCARE
  • Issuance highly unlikely given that JNJ issued $4b and €2.5b already this year.
  • J&J have made 2 major acquisitions in MedTech recently: Shockwave ($13b) and Abiomed ($16.6b) partially offset by the spin-off of Kenvue consumer health.
  • MedTech currently makes up around 36.5% of sales.
  • J&J faces a significant patent cliff with Stelara (12% of sales) now effectively open to competition and Darzalex (12.5%) facing competition after 2029.
  • The company has guided for 10+ assets of >$5b peak year sales by 2030.
  • JNJ equity has underperformed S&P 500 Healthcare by c.-12% this year.
  • The legal exposure to Talcum powder lawsuits is still uncertain. The market was buoyed by a $700m nationwide settlement with 43 states in June but attempts to put legal exposure into a bankruptcy vehicle seem to have stalled.
  • Analysts’ earnings estimates have slipped slightly over the course of the year (FY24 EPS 10.72->10.62) so this is unlikely to be a knockout quarter.
  • Expectations for q-o-q revenue +4.3% with more colour of legal matters, pipeline and MedTech integration.
163 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.
  • Issuance highly unlikely given that JNJ issued $4b and €2.5b already this year.
  • J&J have made 2 major acquisitions in MedTech recently: Shockwave ($13b) and Abiomed ($16.6b) partially offset by the spin-off of Kenvue consumer health.
  • MedTech currently makes up around 36.5% of sales.
  • J&J faces a significant patent cliff with Stelara (12% of sales) now effectively open to competition and Darzalex (12.5%) facing competition after 2029.
  • The company has guided for 10+ assets of >$5b peak year sales by 2030.
  • JNJ equity has underperformed S&P 500 Healthcare by c.-12% this year.
  • The legal exposure to Talcum powder lawsuits is still uncertain. The market was buoyed by a $700m nationwide settlement with 43 states in June but attempts to put legal exposure into a bankruptcy vehicle seem to have stalled.
  • Analysts’ earnings estimates have slipped slightly over the course of the year (FY24 EPS 10.72->10.62) so this is unlikely to be a knockout quarter.
  • Expectations for q-o-q revenue +4.3% with more colour of legal matters, pipeline and MedTech integration.